Overview
cognitive, motor, autonomic, or sensory domains, neurodegenerative
MAY
A complete methodological description of the NAPS Consortium protocol is published in a separate overview paper (Ju et al. Pending). Briefly, participants >18 years of age with polysomnogram‐confirmed RBD by ICSD‐3 criteriaData collection procedures and practices were rigorously standardized across sites, which included structured interviews and questionnaires on health history, structured neurological, and physical examinations, and an objective test battery of cognitive, motor, autonomic, and sensory functions. If available, a co‐participant (a spouse, family member, or friend who knows the participant well) provided information via structured interviews and written questionnaires. Variables presented in this analysis are detailed below; according to the NAPS1 REDCap database export dated May 26, 2022 prior to complete import into the NAPS2 RAVE database. Biofluid assay data, polysomnograms, data from participants enrolling after April 2021, and data from longitudinal study visits are not presented in this analysis.Based on the clinical evaluation, questionnaires, exam, and objective tests, the clinician at each site (a board‐certified neurologist) completed a standardized, structured assessment to render clinical diagnoses. Determinations were supported by a quarterly, panel‐based adjudication process with three or more NAPS clinicians. Participants were categorized as “RBD+” indicating one or more abnormalities (symptoms, signs, or test results attributable to a neurodegenerative cause) in any of the cognitive, motor, autonomic, or sensory domains (